Collplant Biotechnologies Ltd revenue

Collplant Biotechnologies Ltd's revenue was $2.4m in fiscal 2025, up 360.4% on the year before. Since fiscal 2018 ($5.0m) it has grown at a compound -10.1% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Collplant Biotechnologies Ltd: revenue history, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	5	2	6	16	0	11	1	2
Growth on the year before	—	−53.8%	+164.8%	+154.9%	−98.1%	+>999%	−95.3%	+360.4%
Gross profit	3	0	3	14	−0	9	−1	2
Gross margin	66.9%	18.9%	51.1%	87.2%	−33.8%	81.8%	—	64.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Collplant Biotechnologies Ltd	$2.4m	360.4%	—
Korro Bio, Inc.	$2.4m	-62.1%	-53.7%
Vistagen Therapeutics, Inc.	$2.5m	287.3%	—
Korsana Biosciences, Inc.	$1.9m	-12.6%	—
Seres Therapeutics, Inc.	$1.9m	100.0%	-75.6%
Upstream Bio, Inc.	$3.2m	16.0%	—

Compare with peers

Head to head: CLGN vs KRRO CLGN vs VTGN CLGN vs KRSA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Collplant Biotechnologies Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Collplant Biotechnologies Ltd.